186 related articles for article (PubMed ID: 30811663)
1. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study.
Choi YK; Ahn JY; Won SH; Jung K; Na HK; Jung KW; Kim DH; Lee JH; Choi KD; Song HJ; Lee GH; Jung HY
J Gastroenterol Hepatol; 2019 Oct; 34(10):1696-1702. PubMed ID: 30811663
[TBL] [Abstract][Full Text] [Related]
2. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
3. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea.
Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Kim JM; Jung HC
Helicobacter; 2013 Apr; 18(2):135-42. PubMed ID: 23066652
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients.
Lim NR; Kim J; Chung WC
Helicobacter; 2024; 29(1):e13036. PubMed ID: 37985416
[TBL] [Abstract][Full Text] [Related]
8. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
9. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
Xie Y; Zhu Y; Zhou H; Lu ZF; Yang Z; Shu X; Guo XB; Fan HZ; Tang JH; Zeng XP; Wen JB; Li XQ; He XX; Ma JH; Liu DS; Huang CB; Xu NJ; Wang NR; Lu NH
World J Gastroenterol; 2014 Aug; 20(32):11415-21. PubMed ID: 25170230
[TBL] [Abstract][Full Text] [Related]
10. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea.
Lee JH; Kim N; Chung JI; Kang KP; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
Helicobacter; 2008 Aug; 13(4):288-94. PubMed ID: 18665939
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth-containing quadruple therapy in Korea.
Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
Eur J Gastroenterol Hepatol; 2006 May; 18(5):515-9. PubMed ID: 16607147
[TBL] [Abstract][Full Text] [Related]
15. Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy.
Hwang JJ; Lee DH; Kang KK; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Apr; 21(13):3936-43. PubMed ID: 25852279
[TBL] [Abstract][Full Text] [Related]
16. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Liao XM; Nong GH; Chen MZ; Huang XP; Cong YY; Huang YY; Wu BH; Wei JQ
World J Gastroenterol; 2015 May; 21(20):6310-6. PubMed ID: 26034367
[TBL] [Abstract][Full Text] [Related]
17. [Helicobacter pylori: what schemes of eradication are essential today?].
Maev IV; Samsonov AA; Golubev NN
Ter Arkh; 2011; 83(8):41-4. PubMed ID: 21961331
[TBL] [Abstract][Full Text] [Related]
18. [Helicobacter pylori-associated diseases].
Gisbert JP
Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
[TBL] [Abstract][Full Text] [Related]
20. [Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication].
Na HS; Hong SJ; Yoon HJ; Maeng JH; Ko BM; Jung IS; Ryu CB; Kim JO; Cho JY; Lee JS; Lee MS; Shim CS; Kim BS
Korean J Gastroenterol; 2007 Sep; 50(3):170-5. PubMed ID: 17885282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
